GleamWall
中文EN

HYEX HEALTHY EXTRACTS INC.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1630176 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY66.9%
TTM net income YoY-87.1%
TTM EPS YoY—
Revenue 3-yr CAGR31.5%
Net income 3-yr CAGR—

Margins

Gross margin62.4%
Operating margin—
Net margin-36.7%
FCF margin—
EBITDA margin—

Returns

ROE-9.7%
ROA-7.5%
ROIC (approx.)—
Asset turnover0.21x

Leverage & solvency

Liabilities / assets34.0%
Debt / equity0.00x
Current ratio0.14x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.33x
Accruals ratio-10.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$619,326$2.07M$1.61M$1.69M$917,975$968,656$931,280$771,188
Cost of revenue$280,521$614,768$622,043$736,658$470,725$375,828$506,295$356,774
Gross profit$338,805$1.45M$988,701$957,429$447,250$592,827$424,985$414,414
SG&A expense$1.62M$1.50M$1.32M$1.23M$907,363$698,434$533,833$608,524
Interest expense$57,117-$16,469$84,907——-$29,559$34,558—
Income tax$0$0$0$0$0$0$0$0
Net income-$1.71M-$129,389-$200,590-$153,986-$395,394$67,120-$398,860-$446,929
EPS (diluted)————————
Banking
Net interest income-$131,600-$106,632-$84,907-$90,291-$56,172-$29,259-$34,558-$54,984
Balance sheet
Cash & equivalents$143,267$189,958$164,385$146,935$189,452$200,494$118,798$112,020
Receivables$424,270$607,018$253,668$187,750$31,264$3,980$69,981$11,003
Inventory$572,404$644,114$520,752$843,357$966,522$1.11M$1.14M$1.36M
Current assets$1.29M$1.68M$1.09M$1.33M$1.73M$1.56M$1.48M$1.66M
Goodwill$26.18M$26.06M$21.12M$21.12M$193,260$193,260$193,260$193,260
Intangibles$3.73M$3.88M$4.08M$4.23M$21,418$22,052$3,242$3,445
Total assets$32.14M$32.61M$27.32M$27.82M$26.19M$2.50M$2.41M$2.38M
Current liabilities$9.17M$8.39M$1.59M$1.76M$1.17M$861,802$2.35M$1.34M
Total liabilities$10.93M$10.17M$3.34M$3.80M$2.13M$2.02M$2.35M$1.97M
Shareholders' equity$21.20M$22.44M$23.98M$24.03M$24.06M$477,958$60,508$410,377
Shares outstanding15.04M14.74M16.89M16.87M16.87M3.14M2.99M2.99M
Cash flow statement
Operating cash flow-$56,580$306,013$105,970$368,154-$279,871$17,216$60,021$41,878
Investing cash flow-$36,869$95,971$0$75,603$0-$19,302$0$0
Financing cash flow$46,758-$376,411-$88,520-$486,274$268,829$83,782-$53,243-$30,260

Free plan shows the latest 8 periods; Pro shows all 47 🔒

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.